NEUROCRINE BIOSCIENCES, INC.
About NEUROCRINE BIOSCIENCES, INC.
Neurocrine Biosciences, Inc. is a public biotechnology company focused on discovering, developing, and commercializing pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders. Founded in 1992 and headquartered in San Diego, California, the company markets products including INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease, Orilissa for endometriosis, and CRENESSITY for congenital adrenal hyperplasia. It is traded on NASDAQ under NBIX and reported revenues of US$2.86 billion in 2025 with approximately 1,350 employees as of mid-2023.
Investors
Key highlights
- Neurocrine reported net product sales of $583.8 million in Q2 2024, up from $446.3 million year-over-year.
- Maintains a pipeline focused on central nervous system and endocrine disorders with multiple approved products.
- Has completed six funding rounds totaling $1.34B including multiple post-IPO equity and debt financings.
- JPMorgan reported a 5.2% passive stake in the company via SEC Schedule 13G/A filing.
Ask StreetZero about NEUROCRINE BIOSCIENCES, INC.
Put our AI to work on this deal.
Similar companies
Other Public Equity (NASDAQ) deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account